Xvivo Perfusion AB
STO:XVIVO
P/S
Price to Sales
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
Market Cap | P/S | ||||
---|---|---|---|---|---|
SE |
Xvivo Perfusion AB
STO:XVIVO
|
13.6B SEK | 21.2 | ||
CH |
Alcon AG
SIX:ALC
|
39.7B CHF | 4.6 | ||
JP |
Hoya Corp
TSE:7741
|
6.5T JPY | 8.7 | ||
DK |
Coloplast A/S
CSE:COLO B
|
186B DKK | 7.3 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
19.3B USD | 4.9 | ||
US |
Cooper Companies Inc
NYSE:COO
|
17.9B USD | 4.9 | ||
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
59.7B CNY | 14.7 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.1B GBP | 3 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | 234.5 | |
CH |
Ypsomed Holding AG
SIX:YPSN
|
5.2B CHF | 10.3 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 1.5 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.